Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.31B P/E - EPS this Y 49.20% Ern Qtrly Grth -
Income -208.58M Forward P/E -12.87 EPS next Y 43.30% 50D Avg Chg -9.00%
Sales 355.4M PEG -0.24 EPS past 5Y - 200D Avg Chg -27.00%
Dividend N/A Price/Book N/A EPS next 5Y 44.80% 52W High Chg -55.00%
Recommedations 2.00 Quick Ratio 3.31 Shares Outstanding 206.38M 52W Low Chg 3.00%
Insider Own 1.12% ROA -10.85% Shares Float 191.28M Beta 1.96
Inst Own 89.98% ROE - Shares Shorted/Prior 33.64M/32.25M Price 6.95
Gross Margin 39.44% Profit Margin -58.69% Avg. Volume 2,556,691 Target Price 14.00
Oper. Margin -15.62% Earnings Date Aug 1 Volume 5,164,701 Change -0.29%
About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals, Inc. News
05/15/24 Insider Buying: Chief R&D Officer Helen Thackray Acquires 30,000 Shares of BioCryst ...
05/15/24 Director Steven Galson Acquires 21,940 Shares of BioCryst Pharmaceuticals Inc (BCRX)
05/15/24 Insider Buying: Charles Gayer Acquires 30,000 Shares of BioCryst Pharmaceuticals Inc (BCRX)
05/15/24 Insider Buying: CFO Anthony Doyle Acquires Shares of BioCryst Pharmaceuticals Inc (BCRX)
05/14/24 BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
05/13/24 ORLADEYO® (berotralstat) Approved in Mexico
05/09/24 BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
05/09/24 Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results
05/07/24 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
05/07/24 BioCryst to Present at Upcoming Investor Conferences
05/07/24 BioCryst Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
05/07/24 BioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
05/07/24 Q1 2024 BioCryst Pharmaceuticals Inc Earnings Call
05/06/24 Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
05/06/24 BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
05/06/24 BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
05/06/24 BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
05/06/24 BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
05/06/24 BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
05/03/24 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BCRX Chatroom

User Image PharmHand Posted - 2 hours ago

$BCRX A ride Wordle 1,065 5/6* ⬜⬜⬜🟨⬜ ⬜🟩⬜⬜⬜ ⬜🟩⬜⬜⬜ ⬜🟩🟩🟩🟩 🟩🟩🟩🟩🟩

User Image RonIsWrong Posted - 17 hours ago

$BCRX ownership

User Image Sedocan Posted - 23 hours ago

$BCRX have we ever discussed about this material weakness in this board or if any analyst asked any question? Don't know if it is a big deal but just seen this when I go thru their last two reports last night:

User Image YerbMe Posted - 1 day ago

$BCRX I love it when we find out members of the board are loading up on shares. On another note I saw that insiders collectively owned about 95% of the BCRX shares. So let’s say there are 220 millions shares total. 10% is 22 million and half of that (5%) and 11 million shares are owned by the public investor. There aren’t that many shares to gobble up before they own it all. What is your lowest # at which you would sell all your un leveraged shares outright? I would take $20 today and never look back.

User Image Sedocan Posted - 1 day ago

$BCRX remembering Oncternal Therapeutics and Gritstone? The lesson is never follow anyone's advice in social media. Do your own research and take your own decisions. Only a reminder. (Just came to my mind, not trying to say anything with BCRX)

User Image steven1x Posted - 1 day ago

$BCRX https://maximum-pain.com/options/BCRX

User Image gdesivir Posted - 1 day ago

$BCRX Institutional Owners: 423 total, 411 long only, 0 short only, 12 long/short. Institutional Shares (Long): 195,408,533 - 94.69% (ex 13D/G)

User Image steven1x Posted - 1 day ago

$BCRX https://eaaci.org/agenda/eaaci-congress-2024/

User Image steven1x Posted - 1 day ago

$BCRX https://eaaci.org/agenda/eaaci-congress-2024/sessions/systems-medicine/case-report-of-a-patient-with-c1-inhibitor-acquired-angioedema-and-prostate-cancer-treated-with-lanadelumab-relayed-by-berotralstat/

User Image steven1x Posted - 1 day ago

$BCRX old unless you missed https://www.globenewswire.com/en/news-release/2024/05/14/2881234/29446/en/BioCryst-to-Present-New-Data-at-2024-Meeting-of-the-European-Academy-of-Allergy-and-Clinical-Immunology.html

User Image PharmHand Posted - 1 day ago

$BCRX Salty Wordle 1,064 5/6* ⬜⬜⬜🟨⬜ ⬜🟨⬜🟨🟩 ⬜🟩🟩⬜🟩 ⬜🟩🟩⬜🟩 🟩🟩🟩🟩🟩

User Image Paulzk Posted - 1 day ago

$BCRX The European Patent Office (EPO) has opted to maintain the validity of one of Moderna’s key patents in the high-stakes dispute, which is currently playing out in Europe and beyond. The EPO ruling was delivered in a Thursday oral verdict, the Financial Times first reported. The patent in question, referred to as the ‘949 patent, describes “ribonucleic acids containing n1-methyl-pseudouracils" and their potential uses. According to its listing with the EPO, the patent's challengers include Sanofi and GSK as well as partners Pfizer and BioNTech. Over in the Netherlands, the District Court of The Hague shot down Moderna's ‘949 patent last year due to lack of novelty, https://www.fiercepharma.com/pharma/eu-patent-office-backing-key-patent-moderna-wins-one-battle-covid-patent-war-against-pfizer

User Image BillsBowTie Posted - 1 day ago

$BCRX Liisa is assigning a $10 PT within 12 months on Orla alone. Could that be projected out to at least $20 within 4-6 years assuming sales reach peak 1B? Does being cash flow positive add any sort of bonus to PT or is it growing cash on hand that really matters? Could BCRX adopt a solely pre-clinical model, sustain themselves on O alone and just partner molecules for the foreseeable future? Are there other successful companies that have that sort of long-term model?

User Image steven1x Posted - 1 day ago

$BCRX if your curious https://ir.pharvaris.com/news-events/events-presentations/

User Image SilentEarner Posted - 1 day ago

$BCRX hedge short at this point makes zero sense. I don’t even need to explain the reasons.

User Image Jroman23 Posted - 1 day ago

$BCRX i bought today @6.26 and 6.38. HBU?

User Image Stash_Cash Posted - 1 day ago

$BCRX

User Image Dpst2022 Posted - 1 day ago

$BCRX Seem some wild stuff in the past on options expiry fridays. Large volume in the last few mins bringing it down forcefully

User Image fergus0123 Posted - 1 day ago

$BCRX such a clown.

User Image jp19888 Posted - 1 day ago

$BCRX shitshow! big red cAndle again… the first step on the stairs is again taken like al previous times

User Image Psych_Trade79 Posted - 1 day ago

$BCRX Can they do it?!? Will they kill the $6 calls?!? Quite impressive manipulation.

User Image SNOB_ORDER Posted - 1 day ago

$BCRX News from Croatia "New drugs on the list include .....lanadelumab and berotralstat for the prevention of recurrent attacks of hereditary angioedema. https://vijesti.hrt.hr/hrvatska/novi-lijekovi-na-listama-hzzo-a-11545870 https://hzzo.hr/sites/default/files/inline-files/Poziv%203.%20sjednice%20PZL%202024_0.pdf

User Image buy_undervalued_stocks Posted - 1 day ago

$BCRX Welcome new bag holders! Good luck getting your money back anytime soon!

User Image parsnips Posted - 1 day ago

$BCRX holding up well... I'm surprised and impressed. I think I would have been severely disheartened with a retrace. May the reversal hold, and steady move up to fair value continue....

User Image fergus0123 Posted - 1 day ago

$BCRX adding

User Image SNOB_ORDER Posted - 2 days ago

$BCRX News from Italy (and finally Orla is available) https://angioedemaitaca.org/evento/angioedema-day-2024/

User Image tylax30 Posted - 2 days ago

$BCRX but I thought $3.97 was next??

User Image tylax30 Posted - 2 days ago

$BCRX MMs could be back to their fuckery next week but it looks like they’ll be taking it on the chin with the $6 options this week. Love watching them struggle to bring it down.

User Image nickiead Posted - 2 days ago

$BCRX Curious what BO price of board is. Has to be over 3b is my thought. Of course if bird flu mutates all bets off.

User Image Sedocan Posted - 2 days ago

$BCRX to be honest shorts are upset right now

Analyst Ratings
JMP Securities Market Outperform May 7, 24
HC Wainwright & Co. Buy May 7, 24
Needham Buy May 7, 24
Needham Buy Apr 10, 24
Needham Buy Jan 8, 24
Needham Buy Nov 6, 23
RBC Capital Outperform Sep 25, 23
RBC Capital Outperform Sep 18, 23
RBC Capital Sector Perform Aug 4, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Stonehouse Jon P President & CEO President & CEO Feb 01 Sell 10.38 100,000 1,038,000 1,008,739 02/02/23
Stonehouse Jon P President & CEO President & CEO Feb 01 Option 5.45 100,000 545,000 1,108,739 02/02/23
LEE KENNETH B JR Director Director Jan 31 Option 1.71 15,000 25,650 52,118 02/02/23
Sheridan William P Chief Medical Office.. Chief Medical Officer Mar 10 Option 3.22 148,302 477,532 199,093 03/14/22
Sheridan William P Chief Medical Office.. Chief Medical Officer Mar 10 Sell 17.26 161,139 2,781,259 37,954 03/14/22
Jones Michael L Exec. Director, Fina.. Exec. Director, Finance - PAO Mar 01 Option 4.73 2,300 10,879 13,498 03/03/22
Jones Michael L Exec. Director, Fina.. Exec. Director, Finance - PAO Mar 01 Sell 17.2 2,300 39,560 11,198 03/03/22
Stonehouse Jon P President & CEO President & CEO Jan 11 Option 4.73 184,000 870,320 1,085,602 01/13/22
Stonehouse Jon P President & CEO President & CEO Jan 11 Sell 15.04 184,000 2,767,360 901,602 01/13/22
Sheridan William P Chief Medical Office.. Chief Medical Officer Jun 01 Option 5.26 163,573 860,394 106,289 06/01/21
Sheridan William P Chief Medical Office.. Chief Medical Officer Jun 01 Sell 15.01 163,573 2,455,231 14,475 06/01/21
Barnes Alane P Senior VP, Chief Leg.. Senior VP, Chief Legal Officer Dec 15 Option 4.15 13,741 57,025 121,802 12/15/20